Sharing experiences is a way to shorten the path to innovation. Therefore, at the BioVendor Group, in addition to our own research and development, we cooperate on a number of joint projects with scientific and technological institutions.
Our R&D division is a long-established institution in the field of RUO products. At present, it also focuses on applied research of innovative parameters in the field of IVD, especially immunodiagnostics and molecular diagnostics, as well as developments in the field of personalised medicine and point-of-care testing.
Main focus of our research and development teams are new microRNA biomarkers – short non-coding RNAs that are involved in pathogenesis of many diseases, including cancer, cardiovascular or neurodegenerative diseases.
Biovendor R&D has recently obtained a license for the new Two-Tailed RT-qPCR technology, which is a modern tool for the analysis of short molecules of small interfering RNA molecules such as miRNA, piRNA, siRNA and others. This technology, originally developed by TATAA Biocenter company, enables both the qualitative determination of miRNA molecules and their quantification. Based on this platform, tests for the diagnostics of colorectal cancer and bladder cancer are being developed.
The development of automated laboratory technologies is a response to the irreversible trend where automation is becoming a condition for quality and efficient clinical diagnostics.
The goal of our project in the field of automation of in vitro diagnostics is primarily the development of laboratory tests for the diagnosis of inflammation, sepsis, cardiovascular diseases and kidney disease. Diagnostic tests will focus mainly on the determination of innovative protein biomarkers and will function on the principle of chemiluminescent immunoassay. The tests are being developed for a new automated random access platform, i.e., random access analysers.
Another integral part of the development of diagnostic kits is the clinical validation of tests and their certification according to valid IVD legislation.
BioVendor R&D participates significantly in the activities of BIOCEV and CEITEC technology clusters, which serve as a platform for promoting the common goals of companies and universities.
We are currently cooperating on two grant projects:
The project conducted within the TACR’s call of Zéta is focused on the development and validation of innovative detection systems for the determination of urinary miRNA in the diagnosis of urological tumours.
The second joint project is of the RNADIAGON international consortium, whose development and research in the field of the use of non-coding RNA within oncological diagnostics was supported by a grant from Horizon 2020 RISE. In addition to the research team of prof. Slabý from CEITEC and Biovendor R&D, teams from the universities in Graz, Hamburg and Ferrera, as well as the team of Professor Calin from the Anderson Cancer Center in Texas are involved in the project.
Through joint grants, we direct academic research teams to address real problems of practical diagnostics.
For this purpose, we connect workplaces focused on biomarkers with workplaces that are dedicated to developments in the field of laboratory instruments and software.
Few European cities can boast a comparable concentration of innovative companies and research institutions. We are proud of our origin "Made in #brnoregion" and we participate, in close cooperation with the South Moravian Innovation Centre, in shaping the Regional Innovation Strategy of the South Moravian Region.
